Author Archives: rjhealthsystems

Biosimilars are intricate in their makeup and the process for FDA approval is even more multidimensional.  Todd Cooperman’s (PharmD, MBA, R.Ph.) recent whitepaper provides insight into biosimilars in the U.S. healthcare marketplace.  Below is a caption from the introduction of the whitepaper. Initial Food and Drug Administration (FDA) guidance on the biosimilar pathway was intentionally vague, […]